Steve Krognes is our Chief Financial Officer. He is responsible for finance, investor relations, procurement, corporate communications, IT and facilities.
Steve previously worked at Genentech and Roche for twelve years. At Genentech, he served as CFO and as a member of the Executive Committee for six years, where he was responsible for finance, site services and IT. Steve also represented Genentech on the Board and Executive Committee of the California Life Science Association and served as Chairman of the Genentech Access to Care Foundation.
At Roche in Switzerland, Steve led the global Mergers & Acquisition team for more than five years. Under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, including the acquisitions of Ventana Medical Systems and Genentech. Steve worked as an investment banker at Goldman Sachs in London, a management consultant at McKinsey in London, and as a venture capitalist in Stockholm.
Steve holds an M.B.A. from Harvard Business School, a B.S. in economics from the Wharton School of the University of Pennsylvania and is a Second Lieutenant in the Royal Norwegian Air Force.
What is Steve E. Krognes' net worth?
The estimated net worth of Steve E. Krognes is at least $624,109.20 as of September 30th, 2024. Mr. Krognes owns 29,096 shares of Denali Therapeutics stock worth more than $624,109 as of December 22nd. This net worth approximation does not reflect any other assets that Mr. Krognes may own. Learn More about Steve E. Krognes' net worth.
How do I contact Steve E. Krognes?
Has Steve E. Krognes been buying or selling shares of Denali Therapeutics?
Who are Denali Therapeutics' active insiders?
Are insiders buying or selling shares of Denali Therapeutics?
In the last twelve months, insiders at the sold shares 19 times. They sold a total of 274,494 shares worth more than $6,273,411.08. The most recent insider tranaction occured on November, 7th when insider Alexander O Schuth sold 15,558 shares worth more than $465,339.78. Insiders at Denali Therapeutics own 7.9% of the company.
Learn More about insider trades at Denali Therapeutics. Information on this page was last updated on 11/7/2024.
